JP2013500703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500703A5 JP2013500703A5 JP2012522029A JP2012522029A JP2013500703A5 JP 2013500703 A5 JP2013500703 A5 JP 2013500703A5 JP 2012522029 A JP2012522029 A JP 2012522029A JP 2012522029 A JP2012522029 A JP 2012522029A JP 2013500703 A5 JP2013500703 A5 JP 2013500703A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- derivative
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 98
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 77
- 230000027455 binding Effects 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 13
- 102100034256 Mucin-1 Human genes 0.000 claims description 13
- 230000013595 glycosylation Effects 0.000 claims description 13
- 238000006206 glycosylation reaction Methods 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- 102000015728 Mucins Human genes 0.000 claims description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 101100227726 Arabidopsis thaliana FRL3 gene Proteins 0.000 claims description 3
- 101100120609 Caenorhabditis elegans frh-1 gene Proteins 0.000 claims description 3
- 101150023991 FMNL1 gene Proteins 0.000 claims description 3
- 101150005226 FRL1 gene Proteins 0.000 claims description 3
- 101150065691 FRL2 gene Proteins 0.000 claims description 3
- 102100028930 Formin-like protein 1 Human genes 0.000 claims description 3
- 102100032789 Formin-like protein 3 Human genes 0.000 claims description 3
- 101150029401 fmnl3 gene Proteins 0.000 claims description 3
- 229940126618 pankomab Drugs 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000010453 lymph node cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000000163 radioactive labelling Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021109P | 2009-07-31 | 2009-07-31 | |
| EP09009942A EP2281844A1 (en) | 2009-07-31 | 2009-07-31 | MUC 1 antibodies |
| EP09009942.5 | 2009-07-31 | ||
| US61/230,211 | 2009-07-31 | ||
| PCT/EP2010/004663 WO2011012309A1 (en) | 2009-07-31 | 2010-07-30 | Muc1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000133A Division JP6272916B2 (ja) | 2009-07-31 | 2016-01-04 | Ｍｕｃ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500703A JP2013500703A (ja) | 2013-01-10 |
| JP2013500703A5 true JP2013500703A5 (enExample) | 2013-09-05 |
| JP5922018B2 JP5922018B2 (ja) | 2016-05-24 |
Family
ID=41460131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522029A Active JP5922018B2 (ja) | 2009-07-31 | 2010-07-30 | Ｍｕｃ１抗体 |
| JP2016000133A Active JP6272916B2 (ja) | 2009-07-31 | 2016-01-04 | Ｍｕｃ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000133A Active JP6272916B2 (ja) | 2009-07-31 | 2016-01-04 | Ｍｕｃ１抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9217038B2 (enExample) |
| EP (3) | EP2281844A1 (enExample) |
| JP (2) | JP5922018B2 (enExample) |
| KR (1) | KR101773506B1 (enExample) |
| CN (1) | CN102574926B (enExample) |
| AR (1) | AR077334A1 (enExample) |
| AU (1) | AU2010278302B2 (enExample) |
| BR (1) | BR112012002226A2 (enExample) |
| CA (1) | CA2768888C (enExample) |
| CU (1) | CU23972B1 (enExample) |
| EA (1) | EA029954B1 (enExample) |
| IL (1) | IL217827A (enExample) |
| MX (1) | MX2012000874A (enExample) |
| NZ (1) | NZ597563A (enExample) |
| SG (2) | SG177527A1 (enExample) |
| WO (1) | WO2011012309A1 (enExample) |
| ZA (1) | ZA201200166B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150126730A (ko) | 2006-09-10 | 2015-11-12 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| EP1920782A1 (en) * | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| CN103119064B (zh) | 2010-08-10 | 2018-09-04 | 葛莱高托普有限公司 | Fab糖基化抗体 |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| CA2844543A1 (en) | 2011-08-22 | 2013-02-28 | Glycotope Gmbh | Microorganisms carrying a tumor antigen |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| CN105008550B (zh) | 2013-03-01 | 2018-03-30 | 学校法人埼玉医科大学 | 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法 |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| JP6599238B2 (ja) * | 2014-02-06 | 2019-10-30 | 医化学創薬株式会社 | ムチン４（ｍｕｃ４）糖ペプチドに対する抗体及びその用途 |
| RU2016144178A (ru) * | 2014-04-28 | 2018-05-10 | Медисинал Кемистри Фармасьютикалс, Ко., Лтд. | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение |
| WO2016026143A1 (en) | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US11746159B2 (en) | 2015-02-10 | 2023-09-05 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| JOP20190103B1 (ar) | 2016-11-18 | 2023-09-17 | Astellas Pharma Inc | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري |
| JP7162011B2 (ja) * | 2017-01-18 | 2022-10-27 | ナノクルーズ・ファーマシューティカル・リミテッド | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| US20200131275A1 (en) | 2017-03-29 | 2020-04-30 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
| CA3055433A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| MX2020004220A (es) * | 2017-10-24 | 2020-10-05 | Go Therapeutics Inc | Anticuerpos anti-glico-muc1 y sus usos. |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| WO2019221269A1 (ja) * | 2018-05-17 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| CN108982854B (zh) * | 2018-06-19 | 2021-07-27 | 哈尔滨医科大学 | 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用 |
| US12269892B2 (en) | 2018-06-29 | 2025-04-08 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| CN117752825A (zh) | 2018-10-10 | 2024-03-26 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| CN113631229B (zh) | 2019-03-25 | 2025-09-23 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| CN118475617A (zh) * | 2021-12-21 | 2024-08-09 | 美勒斯公司 | 针对与癌症相关的muc1的结合域 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| TW202506190A (zh) | 2023-04-05 | 2025-02-16 | 日商第一三共股份有限公司 | 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| CA2118010C (en) | 1992-04-13 | 2003-10-28 | Donald Kufe | Antibodies specific for carcinoma-associated antigens |
| US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6465220B1 (en) * | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| JP2003519096A (ja) | 1999-08-18 | 2003-06-17 | アルタレックス コーポレーション | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
| GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
| AU2003266236A1 (en) | 2002-07-22 | 2004-02-09 | Nemod Immuntherapie Ag | Method for the production of an immunostimulating mucin (muc1) |
| ES2353753T3 (es) | 2002-08-16 | 2011-03-04 | Glycotope Gmbh | Procedimiento para la producción de lisados de células tumorales inducidas por temperatura para usar como compuestos inmunógenos. |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| DK1654353T3 (da) | 2003-08-18 | 2013-08-26 | Glycotope Gmbh | Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf |
| AU2005215889B9 (en) | 2004-02-13 | 2011-11-17 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| KR20150126730A (ko) | 2006-09-10 | 2015-11-12 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
-
2009
- 2009-07-31 EP EP09009942A patent/EP2281844A1/en not_active Withdrawn
-
2010
- 2010-07-28 AR ARP100102737A patent/AR077334A1/es not_active Application Discontinuation
- 2010-07-30 AU AU2010278302A patent/AU2010278302B2/en active Active
- 2010-07-30 WO PCT/EP2010/004663 patent/WO2011012309A1/en not_active Ceased
- 2010-07-30 US US13/387,587 patent/US9217038B2/en active Active
- 2010-07-30 EA EA201270207A patent/EA029954B1/ru unknown
- 2010-07-30 CN CN201080033969.9A patent/CN102574926B/zh active Active
- 2010-07-30 EP EP18181262.9A patent/EP3421497A1/en active Pending
- 2010-07-30 BR BR112012002226A patent/BR112012002226A2/pt not_active Application Discontinuation
- 2010-07-30 CA CA2768888A patent/CA2768888C/en active Active
- 2010-07-30 SG SG2012000865A patent/SG177527A1/en unknown
- 2010-07-30 SG SG10201404019XA patent/SG10201404019XA/en unknown
- 2010-07-30 KR KR1020127005121A patent/KR101773506B1/ko active Active
- 2010-07-30 NZ NZ597563A patent/NZ597563A/xx unknown
- 2010-07-30 MX MX2012000874A patent/MX2012000874A/es active IP Right Grant
- 2010-07-30 EP EP10746999A patent/EP2459595A1/en not_active Withdrawn
- 2010-07-30 JP JP2012522029A patent/JP5922018B2/ja active Active
-
2012
- 2012-01-09 ZA ZA2012/00166A patent/ZA201200166B/en unknown
- 2012-01-30 CU CU2012000019A patent/CU23972B1/es active IP Right Grant
- 2012-01-30 IL IL217827A patent/IL217827A/en active IP Right Grant
-
2016
- 2016-01-04 JP JP2016000133A patent/JP6272916B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500703A5 (enExample) | ||
| JP7620807B2 (ja) | 抗ＳＩＲＰα抗体およびその適用 | |
| JP2015519375A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| EP4155320A1 (en) | Anti-b7h4 antibody, and bispecific antibody and use thereof | |
| CN114206931A (zh) | 抗pd-1抗体及其用途 | |
| JP2024001073A5 (enExample) | ||
| KR20210027254A (ko) | Tim-3에 대한 항체 및 그의 용도 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JPWO2022111425A5 (enExample) | ||
| JPWO2020157210A5 (enExample) | ||
| JPWO2022207822A5 (enExample) | ||
| US10584175B2 (en) | FN14-binding proteins and uses thereof | |
| JPWO2020163325A5 (enExample) | ||
| IL295993A (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| JPWO2022016190A5 (enExample) | ||
| KR20250069411A (ko) | 항 ceacam5 항체 및 이의 용도 | |
| HK40076375B (zh) | 抗SIRPα抗体及其用途 | |
| JPWO2019165326A5 (enExample) | ||
| RU2025120810A (ru) | Антитела против pdl1, полиспецифические антитела и способы их применения | |
| HK40070091A (en) | Anti-pd-1 antibody and use thereof | |
| JPWO2023109901A5 (ja) | 抗体、免疫コンジュゲート、抗原認識受容体、免疫応答性細胞、医薬組成物、核酸、ベクター、宿主細胞、方法、及びキット |